News

BioSpace1h
Sarepta’s Woes Put the Stalwart AAV Under a Harsh Light
In the wake of multiple patient deaths from liver injuries related to Sarepta Therapeutics’ AAV gene therapy platform, some ...
GEN - Genetic Engineering and Biotechnology News4h
StockWatch: Sarepta Says Deaths of Two Elevidys Patients Posted on FDA Database Unrelated to Treatment
Sarepta Therapeutics said Friday that the deaths of two patients taking its marketed gene therapy Elevidys® (delandistrogene ...
Asianet Newsable on MSN4h
Trump Ally Laura Loomer Calls Vinay Prasad A ‘Marxist Trojan Horse’ After FDA Rehiring, Slams NASA For Dropping Isaacman
Prasad resigned from the FDA in July after backlash over his handling of Sarepta’s Elevidys gene therapy, which faced ...
TipRanks on MSN13h
Sarepta price target raised to $14 from $12 at Citi
Citi raised the firm’s price target on Sarepta (SRPT) to $14 from $12 and keeps a Sell rating on the shares. The company’s Q2 sales beat estimates ...
The Economist13h
America’s drug regulator is in turmoil
T O APPRECIATE the dilemmas the Food and Drug Administration (FDA) faces when it reviews new drugs targeting rare diseases, ...
Notable healthcare headlines for the week: Pfizer, Eli Lilly, UnitedHealth in focus
Pfizer ( PFE) shares gained on Tuesday after the New York-based pharma giant reported better-than-expected financials for Q2 2025 and increased its full-year earnings outlook, citing, among other ...
Sarepta Therapeutics (SRPT) Receives a Sell from Citi
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.